Vandetanib Advantages in Medullary Thyroid Cancer

Peter Langmuir, MD
Published: Tuesday, Mar 15, 2011

Peter Langmuir, M.D. Executive Director, Medical Science AstraZeneca on the Advantages of Vandetanib in Medullary Thyroid Cancer
Peter Langmuir, M.D. Executive Director, Medical Science AstraZeneca on the Advantages of Vandetanib in Medullary Thyroid Cancer

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x